Research from Around the world
Lupus News
The ability to fight disease is a driving force in human survival. Inflammation has emerged as a key weapon in this process. As pathogens change and evolve, the immune system adapts to keep up.
However, to what extent might such evolutionary adaptations also give rise to autoimmune conditions such as lupus and Crohn's disease?
In The Lancet, Ronald van Vollenhoven and colleagues report a positive multicentre double-blind phase 2 randomised, placebo-controlled trial with ustekinumab, an anti-interleukin-12/23 (IL-12/23) monoclonal antibody, in 102 patients aged 18–75 years with active systemic lupus erythematosus (93 women and nine men).
